BBA
ADXN

Baader Bank Aktiengesellschaft’s Addex Therapeutics ADXN Stock Holding History

Baader Bank Aktiengesellschaft’s Portfolio ADXN Stock Details ADXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-960
Closed -$6.58K – 323
2023
Q3 		$6.58K Sell
960
-21
-2% -$212 ﹤0.01% 298
2023
Q2 		$7.93K Buy
+981
New +$14.2K ﹤0.01% 379

Other funds holding ADXN

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
JSC
J. Stern & Co London, United Kingdom $1.03B AUM 20.71% 1-Year Est. Return

Baader Bank Aktiengesellschaft's ADXN Position: Q4 2023 in Review

Baader Bank Aktiengesellschaft sold out of Addex Therapeutics (ADXN) in Q4 2023, closing a stake of 960 shares — an estimated $6.58K sold.

Baader Bank Aktiengesellschaft first reported a position in ADXN in Q2 2023 and held it in 2 quarters. The position peaked at $7.93K in Q2 2023. 3 funds tracked by Wall St. Rank hold ADXN as of Q4 2023.

  • Baader Bank Aktiengesellschaft reported no remaining Addex Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Baader Bank Aktiengesellschaft sold 960 Addex Therapeutics shares in Q4 2023, an estimated $6.58K.
  • Baader Bank Aktiengesellschaft first reported a position in Addex Therapeutics in Q2 2023 and held it in 2 quarters.
  • Baader Bank Aktiengesellschaft's Addex Therapeutics position peaked at $7.93K in Q2 2023.
  • 3 funds tracked by Wall St. Rank held Addex Therapeutics as of Q4 2023.

Based on Baader Bank Aktiengesellschaft's 13F filing for Q4 2023, filed 8 Feb 2024.